Rhumbline Advisers Buys 2,209 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Rhumbline Advisers increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 0.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 481,438 shares of the company’s stock after purchasing an additional 2,209 shares during the quarter. Rhumbline Advisers owned approximately 0.10% of Elanco Animal Health worth $5,830,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AM Squared Ltd purchased a new position in shares of Elanco Animal Health during the third quarter valued at $34,000. Wilmington Savings Fund Society FSB purchased a new stake in Elanco Animal Health in the third quarter worth about $35,000. Farther Finance Advisors LLC grew its holdings in Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after acquiring an additional 2,044 shares in the last quarter. Venturi Wealth Management LLC increased its position in Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the period. Finally, Blue Trust Inc. raised its holdings in shares of Elanco Animal Health by 2,129.2% in the 3rd quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock valued at $57,000 after purchasing an additional 3,790 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

ELAN has been the topic of a number of recent research reports. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health presently has a consensus rating of “Hold” and a consensus target price of $15.57.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $11.15 on Thursday. The firm has a market cap of $5.51 billion, a P/E ratio of 27.88, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The stock has a 50 day moving average of $11.74 and a two-hundred day moving average of $13.06. Elanco Animal Health Incorporated has a 12 month low of $10.20 and a 12 month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $0.08 earnings per share. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. On average, analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.